27 karma · joined April 15, 2012
Insulins are biologic medicines, so once patents expire you might get biosimilar drugs which also require FDA approval, not generics as with other drugs. Admelog is the biosimilar for Humalog, approved by the FDA in early 2018.
As I understand it, Sanofi (Admelog's manufacturer) sets the price to be only slightly below that of Humalog.
Eli Lilly, Novo Nordisk, and Sanofi manufacture substantially all of the insulin, and they more or less follow each other price-wise. There's not the competition you would expect that would drive down prices.
EDIT: they compete by offering varying discounts to particular insurance companies to only cover their insulin at the exclusion of the other company's insulins. This often leads to a letter to patients near the end of the year telling them that the insurance company has decided that their treatment plan has now changed, decisions of their doctor be damned. (Yes, you can appeal and what-not, but it's still fundamentally the insurance company's decision, not your doctor.) This, of course, also screws anyone without insurance who is expected to pay list price.
My comment previously was referring to the best case, where you only lose some toes or a foot in a decade or two.
You might as well say "infected people won't have amputations like we've been doing forever. They must always have the fancy and more convenient antibiotics instead."
The fact is, because of intrinsic differences in the types of insulin, a regimen of NPH and/or R can not help but have a significant increase in diabetic complications (including amputations, as in my statement above) than a basal/bolus regimen of Lantus/Levemir and Novolog/Humalog -- all of which have been available for something like 20 years and all of which have seen predatory price increases.
A suggestion: do the smallest part right now and then look at that as a success. Meaning, don’t worry about planning the whole thing out, with pomodoros and imagination exercises. Those are hurting you because they are keeping your focus on what your mind perceives as a huge mountain of work. Instead, ask yourself, “what is the most stupidly small thing I can do right now?” Have a task to write a new website? First task is to log into your laptop. Once that’s done, next stupidly small thing? Open your text editor. Start with ‘<html>hello</html>’ saved in “index.html”. Keep just doing to most obvious, tiny thing.
Then afterwards, the hardest but most important part: perspective. Don’t look at how much more you could have done if you weren’t procrastinating —- look at how much you got done over a baseline of doing nothing. Hey, I got rails stood up saying “hello world”, but with postgres behind it and it all checked into git. That’s several more things done than if I had done nothing at all. Go me!
I've completed an entire product cycle by myself, more than once, but still work for a company.
Working for a company means I don't have to go out and find the customers, I don't have to do sales and marketing, and I don't have to do the hiring, firing, and day-to-day management of employees. Basically, there's more to running a company than the parts of a product cycle, and insofar as I might be capable of doing all of those other things, I don't enjoy it as much as focusing on solving problems.
Note that while I work at Lulu, I don't officially speak for them.